crizanlizumab   Click here for help

GtoPdb Ligand ID: 10550

Synonyms: Adakveo® | crizanlizumab-tmca | hSel001 [2] | SEG101
Approved drug
crizanlizumab is an approved drug (FDA (2019), EMA (2020))
Compound class: Antibody
Comment: Crizanlizumab is a humanized anti-P-selectin monoclonal that was developed by Selexys Pharmaceuticals (and later acquired by Novartis) as a preventative therapy for sickle cell crises [1]. The antibody and its use are claimed in Selexys' patent WO2012088265A1 [2]. Crizanlizumab was designed to limit complement activation. In clinical trial no anti-crizanlizumab antibodies could be detected [1].
Click here for help
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
P-selectin (CD62) Hs Antibody Binding 8.2 pKd - 2
pKd 8.2 (Kd 5.89x10-9 M) [2]
Description: Binding affinity determined by SPR.